Explore the latest deal across all financial deal types and actionable insights by Theme and Sector to support your business activities and workflows.

United States: Five largest Equity Offering deals by value in the Pharmaceuticals sector (LTM June 2022)

  • A total of 536 Equity Offering deals (pending and completed) were announced in the Pharmaceuticals of United States, in the last twelve months resulting in a total deal value of over $36,917.2 million. In the LTM period, June 2021 turned out to be the most prolific in terms of deal size, with a total deal value of $4,921.9 million, resulting in an average deal value of $104.7 million during that month. On the other hand, the month of March 2022 was the most prolific in terms of deal volume, recording a total of 56 deals, resulting in an average deal value of $59.1 million during that month.

  • Of the 536 deals, the deal secured between Pfizer Inc and Arvinas Inc, was the largest Equity Offering deal in the United States Pharmaceuticals sector, which was valued at $350.0 million and was completed on July 22, 2021. The second-largest deal was between Invus Group LLC; Polaris Partners LLC; Redmile Group LLC; Samsara BioCapital LLC and Scholar Rock Inc, while the third-largest deal was between Avoro Capital Advisors LLC; Invus LP; Janus Henderson Investors; Perceptive Advisors LLC; Pfizer Inc; Redmile Group LLC; Roivant Sciences Inc; Sphera Global Healthcare Master Fund and Amicus Therapeutics Inc; Immunovant Inc; Sema4 OpCo Inc. The Invus Group LLC; Polaris Partners LLC; Redmile Group LLC; Samsara BioCapital LLC-Scholar Rock Inc deal and the Avoro Capital Advisors LLC; Invus LP; Janus Henderson Investors; Perceptive Advisors LLC; Pfizer Inc; Redmile Group LLC; Roivant Sciences Inc; Sphera Global Healthcare Master Fund-Amicus Therapeutics Inc; Immunovant Inc; Sema4 OpCo Inc deal were valued at $205.0 million and $200.0 million, respectively. The fourth-largest deal was between Amgen Inc; Brian Sullivan; Commodore Capital, LP; New Enterprise Associates Inc; RA Capital Management LP; Soleus Capital Management LP; Venrock Healthcare Capital Partners LP-Celcuity Inc; Neumora Therapeutics Inc valued at $100.0 million, whereas the deal between Flagship Pioneering Inc-Evelo Biosciences Inc valued at $79.2 million was the fifth-largest deal.

  • Cumulatively, the top five deals amounted to $1,155.0 million and accounted for nearly 3.13% of the total deals (by value) announced during the last twelve months.

United States: Five largest Equity Offering deals by value in the Pharmaceuticals sector (LTM June 2022)

Published: June 2022
Source: GlobalData

Explore the latest deal across all financial deal types and actionable insights by Theme and Sector to support your business activities and workflows. Explore the latest deal across all financial deal types and actionable insights by Theme and Sector to support your business activities and workflows. Visit Report Store
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward